Genetic Signatures Limited

Equities

GSS

AU000000GSS4

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 02:10:22 2024-06-14 am EDT			5-day change	1st Jan Change
0.675 ^AUD	-3.57%		-10.00%	+55.17%

Jun. 04	Genetic Signatures Limited Announces That the US Food & Drug Administration Has Cleared the Company's Easyscreen? Gastrointestinal Parasite Detection Kit and Gs1 Automated Workflow for Marketing and Sale in the US	CI
Jun. 04	Genetic Signatures Launches AU$30 Million Equity Raising	MT

Genetic Signatures Limited Announces Resignation of Patrick Noland as Non-Executive Director

October 30, 2015 at 06:54 pm EDT

Genetic Signatures Limited announced the resignation of Mr. Patrick Noland as a Non-executive Director of the company to take up his new position in the company as Executive Vice President, US Operations. On September 22, 2015 Genetic Signatures announced the appointment of Mr. Patrick Noland to the full time position of Executive Vice President of US Operations. His resignation as a Director is effective immediately.

Latest news about Genetic Signatures Limited

Genetic Signatures Limited Announces That the US Food & Drug Administration Has Cleared the Company's Easyscreen? Gastrointestinal Parasite Detection Kit and Gs1 Automated Workflow for Marketing and Sale in the US	Jun. 04	CI
Genetic Signatures Launches AU$30 Million Equity Raising	Jun. 03	MT
Genetic Signatures Obtains FDA Clearance for Gastrointestinal Parasite Detection Kit	Jun. 03	MT
Genetic Signatures Appoints CEO	Jun. 03	MT
Genetic Signatures Ceases Development of EasyScreen Essentials Respiratory Product for US Market; Shares Down 11%	May. 26	MT
Genetic Signatures Appoints Interim CEO	Apr. 29	MT
Genetic Signatures' Sales Drop in Fiscal Q3	Apr. 28	MT
Genetic Signatures Secures TGA Approval for Updated EasyScreen Respiratory Pathogen Detection Kit Sale in Australia	Apr. 21	MT
Genetic Signatures Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 21	CI
Genetic Signatures Completes Rights Issue	Jan. 23	MT
Genetic Signatures Closes AU$8 Million Placement	Dec. 28	MT
Genetic Signatures to Raise AU$15.9 Million via Placement	Dec. 25	MT
Genetic Signatures Raises AU$16 Million From Share Sale	Dec. 22	MT
Genetic Signatures Secures AU$7 Million R&D Tax Incentive Rebate for Fiscal Year 2023	Dec. 18	MT
Genetic Signatures Limited Appoints Stephane Chatonsky as Director	Dec. 04	CI
Genetic Signatures Fiscal Q1 Sales Fall 64% Due to Performance Issue	23-10-30	MT
Genetic Signatures Limited(ASX:GSS) dropped from S&P/ASX Emerging Companies Index	23-09-18	CI
Genetic Signatures Submits 510(k) Application to the US FDA to Market Parasite Detection Kit in the US; Shares Jump 17%	23-09-03	MT
Genetic Signatures Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Genetic Signatures Appoints CFO/COO	23-06-15	MT
Genetic Signatures Limited Appoints Karl Pechmann as Chief Financial Officer , Effective 26 June 2023	23-06-15	CI
Genetic Signatures Limited Appoints Karl Pechmann as Chief Operating Officer, Effective 26 June 2023	23-06-15	CI
Genetic Signatures Appoints Interim CFO	23-03-20	MT
Genetic Signatures Limited Announces Management Changes	23-03-20	CI
Genetic Signatures Limited Announces CFO Changes	23-03-20	CI

Chart Genetic Signatures Limited

Duration

Period

More charts

Company Profile

Genetic Signatures Limited is an Australia-based specialist molecular diagnostics (MDx) company. The Company's principal activities include research and commercialization of identifying individual genetic signatures to identify diseases and the sale of associated products into the diagnostic and research marketplaces. The Company is focused on the development and commercialization of its platform technology, 3base. Its MDx 3base platform technology provides high-volume hospitals and pathology laboratories with the ability to screen for an array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. It designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen brand. Its products include EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, EasyScreen Viral Meningitis Detection Kit, and others.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Genetic Signatures Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.675 AUD

Average target price

0.75 AUD

Spread / Average Target

+11.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
GENETIC SIGNATURES LIMITED	+55.17%	100M
DANAHER CORPORATION	+9.81%	189B
INTUITIVE SURGICAL, INC.	+25.79%	150B
BOSTON SCIENTIFIC CORPORATION	+33.09%	113B
SIEMENS HEALTHINEERS AG	+1.98%	65.05B
EDWARDS LIFESCIENCES CORPORATION	+14.58%	52.83B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+2.92%	49.39B
AGILENT TECHNOLOGIES, INC.	-6.56%	38.1B
GE HEALTHCARE TECHNOLOGIES INC.	-2.17%	35.14B
RESMED, INC.	+22.85%	31.2B

Other Advanced Medical Equipment & Technology